p-rsk

Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).

Ravoxertinib (GDC-0994) 是可口服的ERK 激酶抑制剂，抑制ERK1和ERK2的IC50分别为 6.1 和 3.1 nM。